Work Here?
Overview
Company Does Not Provide H1B Sponsorship
Signos provides a wearable device paired with an app to help people manage their metabolism and health. The wearable continuously tracks blood sugar and shows trends, while the app uses that data to offer personalized guidance based on how a user responds to food. The product works by collecting real-time glucose data, analyzing it with AI and a large pool of data, and delivering features like meal- and fasting-related tips, predicted glucose responses for meals, exercise suggestions, and alerts when glucose spikes occur. Signos differentiates itself through metabolism-based, personalized recommendations tied to continuous glucose monitoring, plus in-app nutritionist support and predictive meal insights, all delivered through a subscription. Its goal is to help users lose weight, manage blood sugar, and improve overall health by making informed dietary and lifestyle choices.
About Signos
Industries
Data & Analytics
Hardware
Consumer Software
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$33M
Headquarters
Burlingame, California
Founded
2019
Simplify's Take
What believers are saying
- Subscription pricing at $129–$139/month targets 75% of overweight U.S. adults.[3]
- Integration with smartwatches, scales, Apple Health consolidates health data tracking.[3]
- Positions metabolism as 'fifth vital sign' for continuous real-time monitoring.[4]
What critics are saying
- Dexcom dependency creates single-point-of-failure if biosensor supply disrupts or discontinues.[1]
- GLP-1 medications demonstrate superior efficacy, cannibalizing standalone weight-management market share.[1]
- Insurance reimbursement denial locks out 40–60% of price-sensitive addressable market.[1]
What makes Signos unique
- First FDA-cleared CGM system specifically designed for weight management accessibility.[1]
- AI platform analyzes glucose, food, exercise data for personalized metabolic insights.[1]
- Compatible with GLP-1 medications and post-bariatric surgery as complementary tool.[1]
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$33M
Below
Industry Average
Funded Over
2 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 5%PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ - Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management.
Signos, a comprehensive metabolic health platform that includes a proprietary AI-engine with a continuous glucose monitor (CGM) to provide real-time d
Signos also integrates with smart watches, smart scales and Apple Health data to track metrics.
Wearable startup Signos said Tuesday that it closed a $20 million funding round led by Cheyenne Ventures and GV, formerly Google Ventures.
In lieu of FDA approval, Signos has launched a five-year, 20,000-person study to prove that its app can help people lose weight.
There are no jobs for Signos right now.
Find jobs on Simplify and start your career today
About Signos
Industries
Data & Analytics
Hardware
Consumer Software
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$33M
Headquarters
Burlingame, California
Founded
2019
There are no jobs for Signos right now.
Find jobs on Simplify and start your career today